The third quarter saw a raft of first-in-class approvals, including the first RNA interference (RNAi) drug, the first nanobody, and a novel immunotoxin combining a CD22 Fv antibody fragment and an exotoxin. RNAi, antisense and small molecules achieved clinical milestones in hereditary transthyretin amyloidosis for both neuropathy and cardiomyopathy. Disappointing trial data presented a major setback for indoleamine 2,3-dioxygenase inhibitors in immuno-oncology.

FDA approvals by drug type